Janet M. D. Plate
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Janet M. D. Plate has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Jules E. Harris
Division of Hematology and Oncology, Rush University Medical Center, Chicago, Illinois 60612
3 shared publicationsAileen E. Plate
Division of Oncology and Hematology, Department of Medicine, Rush University Medical Center, Chicago, USA
1 shared publicationClaude M Schofield
1 shared publication- Geetha S Rao
Department of General Surgery, Rush University Medical Center, 1653 W. Congress Parkway, Chicago, IL 60612, USA
1 shared publication Homayoun Shahidi
1 shared publication- Howard L. Kaufman
Rush University Medical Center, Chicago, IL, USA
1 shared publication
Latest Publications
- 1 June 2011
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 10 (6) , 825-836
Clinical trials of vaccines for immunotherapy in pancreatic cancer
A greater understanding of the molecular events that trigger oncogenesis and events that negatively regulate immune responses has allowed for the development of targeted therapies with specific vaccines to match tumor antigens coupled with immunotherapy specifically directed against that tumor's immunosuppressive microenvironment. In order to be effective, vaccine therapies need to both expand the immune response to tumors and overcome immunosuppressive microenvironments therein. Specifically, targeted therapy must be personalized for each cancer patient. While the idea of personalized targeted therapy may seem like a daunting task, it may not be that difficult as it could involve a relatively simple genetic test to identify gene mutations and additional immunohistochemical staining of tumors with antibodies directed against markers of negative immune regulation. The additional cost to personalize cancer therapy with these diagnostic tests is relatively small in comparison to the cost afforded to our healthcare system when inappropriate targeting therapies are administered to patients whose tumors do not express the targets of either the vaccine or the immune modulator. Despite the large cost, cancer patients whose tumors lack the targets of these therapies often receive no benefit from the therapy. The most illogical approach is to develop a study design and perform clinical trials of potential novel targeting drugs without knowledge or confirmation that the patients' tumors express the targets. Current cancer trials for pancreatic cancer patients are discussed in this article.
- 1 June 2011
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 10 (6) , 825-836
Clinical trials of vaccines for immunotherapy in pancreatic cancer
A greater understanding of the molecular events that trigger oncogenesis and events that negatively regulate immune responses has allowed for the development of targeted therapies with specific vaccines to match tumor antigens coupled with immunotherapy specifically directed against that tumor's immunosuppressive microenvironment. In order to be effective, vaccine therapies need to both expand the immune response to tumors and overcome immunosuppressive microenvironments therein. Specifically, targeted therapy must be personalized for each cancer patient. While the idea of personalized targeted therapy may seem like a daunting task, it may not be that difficult as it could involve a relatively simple genetic test to identify gene mutations and additional immunohistochemical staining of tumors with antibodies directed against markers of negative immune regulation. The additional cost to personalize cancer therapy with these diagnostic tests is relatively small in comparison to the cost afforded to our healthcare system when inappropriate targeting therapies are administered to patients whose tumors do not express the targets of either the vaccine or the immune modulator. Despite the large cost, cancer patients whose tumors lack the targets of these therapies often receive no benefit from the therapy. The most illogical approach is to develop a study design and perform clinical trials of potential novel targeting drugs without knowledge or confirmation that the patients' tumors express the targets. Current cancer trials for pancreatic cancer patients are discussed in this article.
- Open Access
- 23 May 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 194
Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: Role of uric acid accumulation in gemcitabine-induced MICA/B expression
Major histocompatibility complex class I-related chain A and B (MICA/B) are two stress-inducible ligands that bind the immunoreceptor NKG2D and play an important role in mediating the cyotoxicity of NK and T cells. In this study, we sought to study MICA/B expression in pancreatic cancer and to determine whether and how genotoxic drugs such as gemcitabine can affect MICA/B expression and natural killer cytotoxity.
- 23 May 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 194
Open AccessMajor histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: Role of uric acid accumulation in gemcitabine-induced MICA/B expression
Major histocompatibility complex class I-related chain A and B (MICA/B) are two stress-inducible ligands that bind the immunoreceptor NKG2D and play an important role in mediating the cyotoxicity of NK and T cells. In this study, we sought to study MICA/B expression in pancreatic cancer and to determine whether and how genotoxic drugs such as gemcitabine can affect MICA/B expression and natural killer cytotoxity.
- 22 November 2010
- Published by Taylor & Francis in Immunotherapy
- Vol. 2 (6) , 757-760
Research Highlights: Immunotherapy to Overcome Lung Tumor Cell-Induced Escape from Immunosurveillance
- 22 November 2010
- Published by Taylor & Francis in Immunotherapy
- Vol. 2 (6) , 757-760
Research Highlights: Immunotherapy to Overcome Lung Tumor Cell-Induced Escape from Immunosurveillance
- 1 October 2007
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 16 (4) , 919-943
Current Immunotherapeutic Strategies in Pancreatic Cancer
- 1 October 2007
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 16 (4) , 919-943
Current Immunotherapeutic Strategies in Pancreatic Cancer
- 15 April 2005
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 94 (6) , 1069-1077
Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer
Genetic alterations are responsible for the development of cancer in ductal cells of the pancreas. These genetic changes result in abnormal molecular expression of proteins that are involved in cell proliferation, cell cycle control and adhesion. Some of the genetic mutations result in aberrant proteins that can be recognized as novel or foreign by cells of innate and adaptive immune systems. These are appropriate targets for therapeutic intervention which may involve immunobiologic approaches. These approaches may be less effective because of immune escape mechanisms developed by tumor cells within the microenvironment of the tumor mass. Immunobiotherapy intervention of pancreas cancer must circumvent these obstacles and integrate effective immunotherapy with molecularly targeted approaches to pancreas cancer intervention.
- 15 April 2005
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 94 (6) , 1069-1077
Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer
Genetic alterations are responsible for the development of cancer in ductal cells of the pancreas. These genetic changes result in abnormal molecular expression of proteins that are involved in cell proliferation, cell cycle control and adhesion. Some of the genetic mutations result in aberrant proteins that can be recognized as novel or foreign by cells of innate and adaptive immune systems. These are appropriate targets for therapeutic intervention which may involve immunobiologic approaches. These approaches may be less effective because of immune escape mechanisms developed by tumor cells within the microenvironment of the tumor mass. Immunobiotherapy intervention of pancreas cancer must circumvent these obstacles and integrate effective immunotherapy with molecularly targeted approaches to pancreas cancer intervention.
- 22 March 2005
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 54 (9) , 915-925
Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas
Effects of gemcitabine (Gemzar) on immune cells were examined in pancreas cancer patients to determine whether it was immunosuppressive, or potentially could be combined with vaccines or other immunotherapy to enhance patient’s responses to their tumors. Blood was obtained at five time-points, before therapy, 3–4 days after initial gemcitabine infusion and immediately preceding three additional weekly infusions. Effects on T-cell subsets, B-cells, myeloid dendritic cell precursors, antigen presenting cells (APC), activated/memory, and naive cells were examined. Functional activity was measured by intracellular staining for cytokines before and after T-cell activation, and by interferon γ production in EliSpot responses to tumor presentation. Although absolute lymphocyte counts decreased with the initial treatment with gemcitabine infusion, the counts stabilized during subsequent treatments, then returned within normal ranges seven days after the fourth treatment so that the absolute lymphocyte count no longer differed significantly from that prior to treatment. These effects on absolute lymphocyte counts were mirrored by statistically significant decreases in absolute numbers of CD3 and CD20 lymphocytes during these time periods. The proportions of T and B-cells, however did not change significantly with therapy, although significance changes were observed in some specialized subsets. A decrease in the proportions of the major BDCA-1+, CD1b myeloid dendritic cell subset and a reciprocal increase in the minor BDCA-3+ dendritic cell subsets resulted at 3–4 days, then their levels returned to normal. No significant changes in percentages of CD86 and CD80 APCs or CD4+, CD25+T-cells were documented. Increased percentages of CD3+, CD45RO+ memory lymphocytes reached significance at day 7, then declined to statistically significant decrease at days 14 and 21 after the second and third infusions, respectively. Immune T-cells were functional in pancreas cancer patients treated with gemcitabine. The data suggest that gemcitabine therapy may decrease memory T-cells and promote naive T-cell activation. We conclude that gemcitabine therapy (1) is not immunosuppressive and (2) may enhance responses to specific vaccines or immunotherapy administered to activate or support immune responses directed toward driving effector immunity to cancer cells.
- 22 March 2005
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 54 (9) , 915-925
Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas
Effects of gemcitabine (Gemzar) on immune cells were examined in pancreas cancer patients to determine whether it was immunosuppressive, or potentially could be combined with vaccines or other immunotherapy to enhance patient’s responses to their tumors. Blood was obtained at five time-points, before therapy, 3–4 days after initial gemcitabine infusion and immediately preceding three additional weekly infusions. Effects on T-cell subsets, B-cells, myeloid dendritic cell precursors, antigen presenting cells (APC), activated/memory, and naive cells were examined. Functional activity was measured by intracellular staining for cytokines before and after T-cell activation, and by interferon γ production in EliSpot responses to tumor presentation. Although absolute lymphocyte counts decreased with the initial treatment with gemcitabine infusion, the counts stabilized during subsequent treatments, then returned within normal ranges seven days after the fourth treatment so that the absolute lymphocyte count no longer differed significantly from that prior to treatment. These effects on absolute lymphocyte counts were mirrored by statistically significant decreases in absolute numbers of CD3 and CD20 lymphocytes during these time periods. The proportions of T and B-cells, however did not change significantly with therapy, although significance changes were observed in some specialized subsets. A decrease in the proportions of the major BDCA-1+, CD1b myeloid dendritic cell subset and a reciprocal increase in the minor BDCA-3+ dendritic cell subsets resulted at 3–4 days, then their levels returned to normal. No significant changes in percentages of CD86 and CD80 APCs or CD4+, CD25+T-cells were documented. Increased percentages of CD3+, CD45RO+ memory lymphocytes reached significance at day 7, then declined to statistically significant decrease at days 14 and 21 after the second and third infusions, respectively. Immune T-cells were functional in pancreas cancer patients treated with gemcitabine. The data suggest that gemcitabine therapy may decrease memory T-cells and promote naive T-cell activation. We conclude that gemcitabine therapy (1) is not immunosuppressive and (2) may enhance responses to specific vaccines or immunotherapy administered to activate or support immune responses directed toward driving effector immunity to cancer cells.
- 26 August 2004
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 45 (8) , 1519-1529
PI3-Kinase Regulates Survival of Chronic Lymphocytic Leukemia B-Cells by Preventing Caspase 8 Activation
(2004). PI3-Kinase Regulates Survival of Chronic Lymphocytic Leukemia B-Cells by Preventing Caspase 8 Activation. Leukemia & Lymphoma: Vol. 45, No. 8, pp. 1519-1529.
- 26 August 2004
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 45 (8) , 1519-1529
PI3-Kinase Regulates Survival of Chronic Lymphocytic Leukemia B-Cells by Preventing Caspase 8 Activation
(2004). PI3-Kinase Regulates Survival of Chronic Lymphocytic Leukemia B-Cells by Preventing Caspase 8 Activation. Leukemia & Lymphoma: Vol. 45, No. 8, pp. 1519-1529.
- 1 November 2000
- Published by Elsevier in Experimental Hematology
- Vol. 28 (11) , 1214-1224
Gene expression in chronic lymphocytic leukemia B cells and changes during induction of apoptosis
- 1 November 2000
- Published by Elsevier in Experimental Hematology
- Vol. 28 (11) , 1214-1224
Gene expression in chronic lymphocytic leukemia B cells and changes during induction of apoptosis
- 1 January 2000
- Published by Begell House Inc. Publishers in Critical Reviews in Immunology
- Vol. 20 (5) , 18-92
Immune Cell Functions in Pancreatic Cancer
Pancreatic cancer kills nearly 29,000 people in the United States annually—as many people as are diagnosed with the disease. Chemotherapeutic treatment is ineffective in halting progression of the disease. Yet, specific immunity to pancreatic tumor cells in subjects with pancreatic cancer has been demonstrated repeatedly during the last 24 years. Attempts to expand and enhance tumor-specific immunity with biotherapy, however, have not met with success. The question remains, "Why can't specific immunity regulate pancreatic cancer growth?" The idea that tumor cells have evolved protective mechanisms against immunity was raised years ago and has recently been revisited by a number of research laboratories. In pancreatic cancer, soluble factors produced by and for the protection of the tumor environment have been detected and are often distributed to the victim's circulatory system where they may effect a more generalized immunosuppression. Yet the nature of these soluble factors remains controversial, since some also serve as tumor antigens that are recognized by the same T cells that may become inactivated by them. Unless the problem of tumor-derived immunosuppressive products is addressed directly through basic and translational research studies, successful biotherapeutic treatment for pancreatic cancer may not be forthcoming.
- 1 January 2000
- Published by Begell House Inc. Publishers in Critical Reviews in Immunology
- Vol. 20 (5) , 18-92
Immune Cell Functions in Pancreatic Cancer
Pancreatic cancer kills nearly 29,000 people in the United States annually—as many people as are diagnosed with the disease. Chemotherapeutic treatment is ineffective in halting progression of the disease. Yet, specific immunity to pancreatic tumor cells in subjects with pancreatic cancer has been demonstrated repeatedly during the last 24 years. Attempts to expand and enhance tumor-specific immunity with biotherapy, however, have not met with success. The question remains, "Why can't specific immunity regulate pancreatic cancer growth?" The idea that tumor cells have evolved protective mechanisms against immunity was raised years ago and has recently been revisited by a number of research laboratories. In pancreatic cancer, soluble factors produced by and for the protection of the tumor environment have been detected and are often distributed to the victim's circulatory system where they may effect a more generalized immunosuppression. Yet the nature of these soluble factors remains controversial, since some also serve as tumor antigens that are recognized by the same T cells that may become inactivated by them. Unless the problem of tumor-derived immunosuppressive products is addressed directly through basic and translational research studies, successful biotherapeutic treatment for pancreatic cancer may not be forthcoming.